30th week of 2018 patent applcation highlights part 8 |
Patent application number | Title | Published |
20180207082 | HAIR COMPOSITION - The present invention provides: an aqueous hair care composition comprising; a. 0.5 to 3 w.t. of cationic polymer, b. one or more hair benefit agents, wherein the composition is substantially free of fatty materials, and wherein the benefit agent is selected from glycerine and silicone. | 2018-07-26 |
20180207083 | HAIR COMPOSITION - The present invention provides a hair treatment composition comprising; a. 40-99 w.t. % of a dispersion of a loosely reticulated silicone elastomer solvent; b. a compound selected from; i. 0.005-8 w.t % temporary dye ii. 0.005-12 w.t. % semi-permanent dye iii. 0.001-6 w.t. % pigment and mixtures thereof, c. 0.005 w.t. % to 59 w.t. % carrier material | 2018-07-26 |
20180207084 | NAIL CARE SYSTEM - The present invention relates to a nail care system containing (1) at least one composition containing at least one adhesive agent, at least one primary film former and at least one plasticizer; and (2) an applicator. | 2018-07-26 |
20180207085 | COSMETIC COMPOSITION - Cosmetic composition for healing and treating the skin, the formula of which consists exclusively of compounds functional for the skin and/or compounds functional both for the skin and also for the structure of the formula. | 2018-07-26 |
20180207086 | EMOLLIENT COMPOSITION - The present invention relates to an emollient composition comprising emu oil, jojoba oil, a dermatological base and a metal or metalloid oxide, hydroxide or carbonate. The composition has efficacy in the prevention or treatment of a range of skin conditions. | 2018-07-26 |
20180207087 | KIT AND AESTHETIC SYSTEM FOR PREVENTION OF SKIN AGING - A kit and an aesthetic system for the prevention of skin aging includes a telomerase activating composition, a skin dermis irradiating laser, a composition for topical fat removal including a hyaluronidase, and a skin muscle layer irradiating laser, as well as a process for preventing skin aging in humans using said kit and system. The kit and aesthetic system for the prevention of skin aging have comprehensive effects concerning skin aging including instantaneous wrinkle improvement, skin contouring, elasticity enhancement, wrinkle improvement, topical fat removal, and skin hydration improvement as well as long-lasting maintenance effects up to 1 year to 1.5 years, despite their short treatment time. | 2018-07-26 |
20180207088 | Daily Face Cream - This invention is a natural face cream/lotion that exploits the benefits of Dead Sea salt for helping moisturize the skin of a human face. The lotion consists of natural ingredients such as organic aloe vera juice, shea butter, preferably unrefined, emulsified wax, Dead Sea salt, hydrolyzed wheat protein, essential oils (particularly lavender, rosehip seed oil and carrot seed oil), apple cider vinegar, and xanthan gum. They are included with a preservative made from leuconostoc/radish root ferment filtrate and phenoxyethanol. | 2018-07-26 |
20180207089 | ACID CONTAINING LIPID FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of:
| 2018-07-26 |
20180207090 | INTRA-MAMMARY TEAT SEALANT FORMULATION AND METHOD OF USING SAME TO REDUCE OR ELIMINATE VISUAL DEFECTS IN AGED CHEESES - Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a teat seal formulation including a metal salt in a glyceride-containing gel base into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated. | 2018-07-26 |
20180207091 | Novel methods for delivering therapeutic agents to the eye via nasal passages - The invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. The invention is specifically directed to treating disorders, diseases and injuries of the cornea and ocular surface, treating retinal disorders, diseases and injuries and optic nerve disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. | 2018-07-26 |
20180207092 | METHOD FOR PREVENTING NASOLACRIMAL DUCT OBSTRUCTION - The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer. The method includes administering an effective amount of perchlorate anion to the eyes of the patient. | 2018-07-26 |
20180207093 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS - The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles. | 2018-07-26 |
20180207094 | IMPROVED TOPICAL KETOPROFEN FORMULATIONS - A topical formulation comprising an oil-in-water (o/w) emulsion of ketoprofen in a racemic or (s)-enantiomer form is provided herein. In some embodiments, the topical formulation is a cream. In some embodiments, the topical formulation includes one or more oily substances, higher alcohols, drug solubilizing vehicles, surfactants, permeation enhancers, buffering agents, antioxidants, preservatives, and water. | 2018-07-26 |
20180207095 | CELL TISSUE GEL CONTAINING COLLAGEN AND HYALURONAN - Described herein is a cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1. | 2018-07-26 |
20180207096 | Negatively Charged Self-Assembling Supported Lipid Bilayer On Mesoporous Silica Nanoparticles, Method Of Synthesis And Use As A Nanovector - A method for manufacturing a negatively charged supported lipid bilayer. The method comprises the steps of preparing a formulation comprising at least three lipids (1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), cholesterol and at least one lipid different from DOPS and cholesterol) dissolved in a first solvent, of evaporating the first solvent, of adding an aqueous formulation of mesoporous silica nanoparticles, of performing an ultra-sonication and of performing a centrifugation. The method is remarkable in that the number of equivalents of cholesterol relative to one equivalent of DOPS is comprised between 2.30 and 2.70. Additionally, negatively charged supported lipid bilayer on a mesoporous silica nanoparticle comprising cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and at least one lipid different from DOPS and cholesterol. | 2018-07-26 |
20180207097 | NON-TOXIC VEHICLE TO SOLUBILIZE, DELIVER, AND OBTAIN BIOLOGICAL ACTIVITY OF STEROID HORMONES AT CELL, TISSUE, AND ORGAN TARGETS, IN VITRO AND IN VIVO - A non-toxic vehicle for hormone therapy. The non-toxic vehicle includes a cationic lipid or a neutral lipid and polyethylene glycol. | 2018-07-26 |
20180207098 | Composition for the Treatment of Fistula - A composition for use in the treatment of fistula, the composition comprising activated carbon. | 2018-07-26 |
20180207099 | NON-MECHANICAL PROCESS FOR THE MICRONIZATION OF DIGOXIN - New non-mechanical process of micronization, capable to reduce the particle size of digoxin from ordinary level to a selected micrometer range. Micronization is obtained via a specific treatment, to be performed on a purified and concentrated digoxin solution in an organic solvent. The purified and concentrated digoxin solution is obtainable via a sequence of solvent treatments; then, after reaching the required concentration, the solution is further concentrated, obtaining the precipitation of digoxin; the reaction mixture is then added with methanol under stirring for a suitable time. The recovered precipitate consists in a digoxin with particle size comprised between 20 and 30 micrometers for at least 90% by weight of the obtained particles, and is exempt from degradation products. | 2018-07-26 |
20180207100 | SOLID DOSAGE FORMS OF PALBOCICLIB - The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics. | 2018-07-26 |
20180207101 | PULVERULENT, DIRECTLY COMPRESSIBLE POLYVINYL ALCOHOL GRADES - The present invention relates to premixes for the production of active compound-containing tablets which comprise polyvinyl alcohols (PVAs). The invention also relates to active compound-containing tablets which comprise a corresponding premix. | 2018-07-26 |
20180207102 | Pharmaceutical Composition Containing Celecoxib and Tramadol - The present invention relates to a complex containing celecoxib and tramadol. The present invention is designed such that, even though two different active ingredients are prepared into a single dosage form, the release patterns of respective drugs are optimized in the expression of synergy effects, with respect to pain, of the respective drugs, through the new prescription. | 2018-07-26 |
20180207103 | USE OF AN INJECTABLE ANTIMICROBIAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF OSTEOARTHRITIS - In one form of the invention, there is provided a method for treating osteoarthritis, the method comprising applying a broad spectrum antimicrobial formulation to the subchondral bone of a mammal. In another form of the invention, there is provided a pharmaceutical composition for treating infections, including infections leading to arthritis. | 2018-07-26 |
20180207104 | IMPROVED NANOPARTICLE DELIVERY SYSTEMS - Nanopaiticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered. | 2018-07-26 |
20180207105 | METHOD FOR MANUFACTURING A THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTIONS - A method of manufacturing a therapeutic agent for the treatment of infections includes the steps of preparing a homogeneous solution of poly(DL-lactide-co-glycolide acid), preparing a solution of a peroxygen donor, preparing a solution of an acetyl donor, adding each of the solutions to a quantity of the poly(DL-lactide-co-glycolide acid) solution to produce a resultant mixture, preparing encapsulated nano- or micro-scale particles from the resultant mixture using a microencapsulator, collecting the nano- or micro-scale particles, and subsequently subjecting the particles to a lyophilization process. | 2018-07-26 |
20180207106 | PROTEIN COATING COMPOSITION - The invention relates generally to the field of nanoparticles, and more specifically, in one embodiment, to bio-nanoparticle elements formed from materials comprised of self-assembling protein molecules, which are capable of coating one or more type of elements. In another invention embodiment, the invention relates to a protein that coats one or more elements in order to modify or improve one or more characteristic of the element, including, but not limited to, stability, rigidity, or functionality of the element that is coated with the instant invention. | 2018-07-26 |
20180207107 | NANOPARTICLES CONTAINING EXTRACELLULAR MATRIX FOR DRUG DELIVERY - Nanoparticles coated with extracellular matrix (ECM) are provided, in some aspects, for the delivery of a therapeutic protein, nucleic acid, or drug. In some embodiments, the nanoparticles are delivered to a subject via inhalation or aerosol delivery. Also provided, in some aspects, are methods for treating acute lung injury comprising administering α-Klotho (αKlotho) protein or DNA to a subject. | 2018-07-26 |
20180207108 | Method for Manufacturing Asenapine-Containing Patch - The present invention provides a method for manufacturing a patch comprising a backing and an adhesive layer laminated on the backing, comprising: a step of mixing an acid addition salt of asenapine, a (meth)acrylic acid ester (co)polymer and a desalting agent to obtain an adhesive composition; and a step of shaping the adhesive composition to obtain the adhesive layer. | 2018-07-26 |
20180207109 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS - The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy. | 2018-07-26 |
20180207110 | COMPOSITION AND METHOD FOR INHIBITION OF NERVE TRANSMISSION - The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form. | 2018-07-26 |
20180207111 | IMMUNOTHERAPY FOR CASR-EXPRESSING CANCER (E.G. NEUROBLASTOMA) - Methods for increasing susceptibility of cancer cells to immunotherapeutic agents and methods for assessing the effectiveness of a cancer treatment. | 2018-07-26 |
20180207112 | COMPOUNDS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS - The present invention provides compositions and methods of their use in treating dystroglycanopathy, muscular dystrophy and other disorders. | 2018-07-26 |
20180207113 | VIVO INTRACELLULAR REPROGRAMMING COMPOSITION AND METHOD OF MAKING AND USING SAME - An in vivo intracellular reprogramming method for both somatic and stem cell pools in the mammal's body using, C60 fullerenes can be added to enhance mitochondrial ATP production and Biogenesis, Metformin, Everolimus, Seligilene, Danasitab, Venetoclaxalong with Quercitin may act as agent to enhance autophagy and apoptosis helping to decrease their ongoing formation and a novel resveratrol complex along ribonucleasies worth together to help decrease heterchromation dysregulation aid in DNA repair enhancement and nutraceuticals is disclosed. The present in vivo reprogramming invention works at the epigenetic level and promotor region of the genome inside the nucleus of the cell, and other intracellular organelles, rather than outside the body. The key genetic activity changes that the invention reverses have now been found responsible for causing aging in adult stem cells and somatic cells, the combination of the above compounds have been shown to cause improved and corrected epigenetic changes or reprogramming in vivo in gene expression to induce the necessary genetic changes to improve cellular aging and epigenetic IC changes responsible for the changes and therefore effect total body and cellular health from the organ and tissue level on upward. The key to and extended to a long and healthy life is keeping your somatic cells health and maintaining a pool of stem cells can be called on for acute situations like healing form surgery or trauma or an immune boast to frequent infection. | 2018-07-26 |
20180207114 | ESTROGEN RELATED RECEPTOR GAMMA (ERRgamma) ENHANCES AND MAINTAINS BROWN FAT THERMOGENIC CAPACITY - Brown adipose tissue (BAT) plays a role in keeping an organism warm in response to a cold environment. In response to cold, transcription factors, including peroxisome proliferator receptor alpha (PGC1α), mediate the adaptive changes in the expression of oxidative and thermogenic genes in BAT. However, even without cold, BAT exhibits high expression of these genes relative to white adipose tissue (WAT). It is shown herein that estrogen related receptor gamma (ERRγ) is a critical factor that controls the expression of key metabolic genes in BAT under basal conditions. ERRγ is highly expressed in BAT versus WAT, yet is not transcriptionally induced by cold, suggesting it plays an important role in innate basal BAT function rather than in the adaptive response to cold. Based on these observations, methods of increasing thermogenesis in a subject by administering a therapeutically effective amount of one or more agents that increase ERRγ activity are provided. | 2018-07-26 |
20180207115 | DERMATOMYCOSIS TREATMENT AGENT - Provided is a means effective in treating dermatomycosis. An external therapeutic agent for treating dermatomycosis containing a trialkali metal salt of citric acid. | 2018-07-26 |
20180207116 | METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEDG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEDG - Methods of quantifying N | 2018-07-26 |
20180207117 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS - Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. | 2018-07-26 |
20180207118 | AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES - This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed. | 2018-07-26 |
20180207119 | AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERS - This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof. | 2018-07-26 |
20180207120 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, OR ALLEVIATING OBESITY OR RELATED DISEASES - A composition comprising azelaic acid as an active ingredient suppresses accumulation of lipids in adipose tissue and improves lipid metabolism in adipose tissue. | 2018-07-26 |
20180207121 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF - This invention relates to compositions and methods for the therapy and diagnosis of neurodegenerative or neuromuscular disorders. More particularly, this invention relates to use of anaplerotic agents for treating, preventing, or delaying the onset of a neurodegenerative or neuromuscular disorder. | 2018-07-26 |
20180207122 | METHODS OF REDUCING MICROBIAL CONTAMINATION - Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided. | 2018-07-26 |
20180207123 | CERAMIDE DERIVATIVES AS ANTICANCER AGENTS - The invention provides a compound of formula (I): (I) wherein R | 2018-07-26 |
20180207124 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT - The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) | 2018-07-26 |
20180207125 | ISOCHROMAN COMPOUNDS AND METHODS OF USE THEREOF - The invention provides compounds of formula I: | 2018-07-26 |
20180207126 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula I: | 2018-07-26 |
20180207127 | Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same - The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism. | 2018-07-26 |
20180207128 | IMMUNOSUPPRESSANT FORMULATION - The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form. | 2018-07-26 |
20180207129 | LICOFELONE DERIVATIVES AND METHODS OF USE - Derivatives of licofelone for the treatment of chronic inflammatory diseases and epithelial cancers associated with chronic inflammation are disclosed. The agents target mPGES-1 and 5-LOX. | 2018-07-26 |
20180207130 | FORMULATIONS COMPRISING TRIPTAN COMPOUNDS - The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T | 2018-07-26 |
20180207131 | PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER - The present invention provides and a plastic container and multilayered films, which comprises a heat-sealable seal layer, a cyclic polyolefin layer, and an outermost layer, wherein the seal layer comprises polypropylene, the cyclic polyolefin layer comprises a cyclic polyolefin polymer or a cyclic polyolefin copolymer, and the outermost layer comprises a layer containing polypropylene, and which further comprises a resin composition layer comprises a blended product of a propylene polymer and a styrene elastomer. The plastic container of the present invention can suppresses a reduction in the medicament content of a liquid-state medicament and is excellent in terms of shock resistance, handling ability during the filling of the container with the medicament, and the moldability and transparency of the container. | 2018-07-26 |
20180207132 | SPIROCYCLIC COMPOUNDS - Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein. | 2018-07-26 |
20180207133 | ANESTHETIC COMPOSITIONS AND METHODS COMPRISING IMIDAZOLINE COMPOUNDS - Effective implantable medical devices and methods for reducing and treating acute pain by providing local anesthesia and nerve blockade using an imidazoline compound, such as clonidine are provided. In some embodiments, there is an injectable pharmaceutical composition comprising a therapeutically effective amount of imidazoline compound in a liquid pharmaceutical carrier, where the imidazoline compound provides local anesthesia and nerve block to the target tissue site which is a dorsal root ganglion, peripheral nerve fiber and/or peripheral nerve root. | 2018-07-26 |
20180207134 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION - The present invention concerns compositions for the increase in the humoral secretion comprising imidazole peptides or extracts containing them, as well as the use of said compositions for the prevention and/or treatment of secretarial dysfunctions of the body mucosa. | 2018-07-26 |
20180207135 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS - Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence. | 2018-07-26 |
20180207136 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO - The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject. | 2018-07-26 |
20180207137 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS - The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R | 2018-07-26 |
20180207138 | METHODS FOR THE TREATMENT OF TREMORS BY POSITIVE MODULATION OF SK CHANNELS - Provided herein is the use of one or more small-conductance calcium-activated potassium channel positive modulators (SK positive modulators) for the treatment of tremors. | 2018-07-26 |
20180207139 | IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITION OF TIZANIDINE - The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives. | 2018-07-26 |
20180207140 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation - Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis. | 2018-07-26 |
20180207141 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2018-07-26 |
20180207142 | AVIBACTAM AND CARBAPENEMS ANTIBACTERIAL AGENTS - Described are methods of treating or preventing a bacterial infection by administering an antibacterial agent comprising a β-lactamase inhibitor and one or more carbapenem to a subject. | 2018-07-26 |
20180207143 | Aqueous Suspensions Of Oximes For Autoinjectors - The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors. | 2018-07-26 |
20180207144 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS - This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. | 2018-07-26 |
20180207145 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES - Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease. | 2018-07-26 |
20180207146 | PHARMACEUTICAL COMPOSITION COMPRISING 5ALPHA-REDUCTASE INHIBITOR - Disclosed is a composition comprising a 5α-reductase inhibitor. Forming a liquid crystal upon exposure to an aqueous fluid, the composition can release the 5α-reductase inhibitor at a constant rate over a long period of time. In addition, the composition can significantly alleviate irritations attributed to the topical administration of the 5α-reductase inhibitor, and thus the composition has improved safety. | 2018-07-26 |
20180207147 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO - The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (notably neuropathic pain, neurodegenerative disorders, ischemic brain injury and inflammatory intestinal conditions). Additionally, the invention provides a method to enhance the therapeutic effect of amitriptyline for its common indications. The method of the invention involves combining amitriptyline with another HC-blocking agent, mefloquine. | 2018-07-26 |
20180207148 | THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER - The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from cancer. | 2018-07-26 |
20180207149 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION - Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition. | 2018-07-26 |
20180207150 | COMPOUNDS AND ANTI-TUMOR NQO1 SUBSTRATES - Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy. | 2018-07-26 |
20180207151 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2018-07-26 |
20180207152 | ANTICOAGULANT REVERSAL AGENTS - Novel anticoagulant reversal compounds are disclosed, as well as methods of making the compounds, pharmaceutical compositions including the compounds, methods of using the compounds to reverse the anticoagulant effects of coagulation inhibitors, and diagnostic assays comprising the compounds. | 2018-07-26 |
20180207153 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative N represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like. | 2018-07-26 |
20180207154 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor - Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-δinhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-δ inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer. | 2018-07-26 |
20180207155 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS - This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV. | 2018-07-26 |
20180207156 | DIHYDROINDENE AND TETRAHYDRONAPHTHALENE COMPOUNDS - The invention provides compounds of formula I: | 2018-07-26 |
20180207157 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6- -(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)- METHANONE CITRATE - The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyetetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same. | 2018-07-26 |
20180207158 | 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS - There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD. | 2018-07-26 |
20180207159 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME - Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein. | 2018-07-26 |
20180207160 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 - The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27. | 2018-07-26 |
20180207161 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS - Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer. | 2018-07-26 |
20180207162 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRI- MIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE - A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or | 2018-07-26 |
20180207163 | Methods and compositions for treating solid tumors and other malignancies - A combination of a CDK4/6 inhibitor and an mTOR inhibitor for the treatment of cancer. | 2018-07-26 |
20180207164 | COMBINATION THERAPIES FOR TREATING CANCERS - Methods for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a BTK inhibitor and a BCL-2 inhibitor or pharmaceutically acceptable salts or hydrates thereof, a Btk inhibitor and a Syk inhibitor or pharmaceutically acceptable salts or hydrates thereof, and administration of a Btk inhibitor and a P13K inhibitor or pharmaceutically acceptable salts or hydrates thereof. | 2018-07-26 |
20180207165 | METHODS AND COMPOSITIONS FOR STIMULATING BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT - The invention relates to supporting the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract of an animal. Provided is the use of riboflavin, riboflavin phosphate or a salt thereof, for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of Faecalibacterium prausnitzii in the gastrointestinal tract. Also provided is a synbiotic composition comprising living beneficial butyrate-producing anaerobic bacteria formulated with riboflavin, riboflavin phosphate or a salt thereof, and cysteine. | 2018-07-26 |
20180207166 | Compounds and Compositions for Ossification and Methods Related Thereto - The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 2018-07-26 |
20180207167 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS - Disclosed is an inhibitor of calcineurin of the setron family for use for treating hearing loss in a subject in need thereof. | 2018-07-26 |
20180207168 | DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA - The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin. | 2018-07-26 |
20180207169 | METHODS OF PREVENTING TOXICITY OF PLATINUM DRUGS - Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof. | 2018-07-26 |
20180207170 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES - The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2018-07-26 |
20180207171 | SALT OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,- 3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT - 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II): | 2018-07-26 |
20180207172 | TREATMENT FOR VITILIGO - A method of treating vitiligo, including prophylaxis, in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a compound of Formula (I): | 2018-07-26 |
20180207173 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS - Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer. | 2018-07-26 |
20180207174 | Hypotensive lipid-containing biodegradable intraocular implants and related methods - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma. | 2018-07-26 |
20180207175 | COMPOSITION FOR LOWERING INTRAOCULAR PRESSURE - A tears-resistant and enduring intraocular pressure lowing composition comprises an intraocular pressure lowering drug, a mucoadhesive polymer, a PH sensitive polymer, and a solvent. When a PH is less than or equal to 7.03, the intraocular pressure lowing composition is in a liquid form, when the PH is greater than 7.03, the intraocular pressure lowing composition is in a gel form. The gel form of intraocular pressure lowering composition is not easily washed out by tears, so when the intraocular pressure of an eye is normal, the intraocular pressure lowering composition dropped in the eye is in gel form, thereby the intraocular pressure lowering composition can be retained in the eye for a long time. | 2018-07-26 |
20180207176 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN - A method for contraception includes administering to a female daily, during a time period of 21 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein the drug formulation is administered in a biphasic dosing regimen comprising a 14 day phase and a 7 day phase, wherein doses of each of the norethindrone acetate and EE in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the norethindrone acetate and EE administered during the first phase of the regimen, wherein the norethindrone acetate dose in the first phase is 1000 mcg and in the second phase is 1500 mcg, wherein the EE dose in the first phase is 20 mcg and in the second phase is 30 mcg, and wherein the biphasic dosing regimen is followed by 7 days without norethindrone acetate and EE administration. | 2018-07-26 |
20180207177 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2) - A hormone modulator for causing cellular apoptosis in triple-negative breast cancer cells. The hormone modulator includes at least one of Δ5-androsten-3β,17β-diol and Δ5-androsten-3β,7β,17β-triol and estradiol. | 2018-07-26 |
20180207178 | TOPICAL FORMULATIONS COMPRISING A STEROID - The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders. | 2018-07-26 |
20180207179 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS - The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by | 2018-07-26 |
20180207180 | METHODS FOR TREATING AND PREVENTING NOCICEPTIVE PAIN - Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof. | 2018-07-26 |
20180207181 | REDUCING THE REPRODUCTIVE CAPACITY OF MAMMALS - Provided are compositions and methods for reducing the reproductive capacity of mammals. The compositions and methods involve the use and administration of (a) a diterpenoid epoxide comprising a triptolide skeleton and which causes ovarian follicle depletion in female mammals and (b) an organic diepoxide which causes ovarian follicle depletion in female mammals. | 2018-07-26 |